middle Dose

DRUG3 trials

Sponsors

The First Affiliated Hospital of Anhui Medical University, Shulan (Hangzhou) Hospital, Beijing Northland Biotech. Co., Ltd.

Conditions

Acute Myocardial InfarctionChronic hepatitis BHeterozygous Familial Hypercholesterolemia

Early Phase 1

A Single-Center, Open-label, Single-Arm, Dose Escalation and Dose Extension Investigator-Initiated Study (IIT) to Evaluate the Safety, Efficacy and Pharmacokinetic of EPI-001 Injection for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH)

Active, not recruitingChiCTR2400081208

The First Affiliated Hospital of Anhui Medical UniversityHeterozygous Familial Hypercholesterolemia

Start: 2024-02-27Updated: 2024-03-04

A study on the safety, tolerance, pharmacokinetics and pharmacodynamics of EPI-003T injection in the treatment of chronic hepatitis B subjects who have been treated with nucleoside (acid) analogues

Active, not recruitingChiCTR2500110861

Shulan (Hangzhou) HospitalChronic hepatitis B

Start: 2025-10-22Updated: 2025-10-27

Phase 2

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

CompletedNCT05485818

Beijing Northland Biotech. Co., Ltd.Acute Myocardial Infarction

Start: 2020-11-23End: 2021-11-18Updated: 2022-08-03